References
- 1. D. C. Baumgart, Treatment of inflammatory bowel disease: A review of medical therapy, World J. Gastroenterol. 21 (2008) 354-377; DOI: 10.3748/wjg.14.354.
- 2. U. Klotz and M. Schwab, Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease, Adv. Drug Deliv. Rev. 57 (2005) 267-279; DOI: 10.1016/j.addr.2006.09.011.
- 3. M. Jiménez and A. S. Peña, Budesonide for ulcerative colitis, Rev. Esp. Enferm. Dig. 98 (2006) 362-373; DOI: 1130-0108/2006/98/5/362-373.
- 4. K. Dilger, M. Alberer, A. Busch, A. Enninger, R. Behrens, S. Koletzko, M. Stern, C. Beckmann and C. H. Gleiter, Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn’s disease, Aliment. Pharmacol. Ther. 23 (2006) 387-395; DOI: 10.1111/j.1365-2036.2006. 02771.x.
- 5. J. Seidegård, L. Nyberg and O. Borgå, Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole, Eur. J. Pharm. Sci. 15 (2008) 264-70; DOI: 10.1016/j.ejps.2008.07.005.
- 6. L. F. Asghar and S. Chandran, Multiparticulate formulation approach to colon specific drug delivery: current perspectives, J. Pharm. Pharm. Sci. 9 (2006) 327-338.
- 7. Y. Krishnamachari, P. Madan and S. Lin, Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon, Int. J. Pharm. 29 (2007) 238-47; DOI: 10.1016/j.ijpharm.2007.02.015.
- 8. A. Makhlof, Y. Tozuka and H. Takeuchi, pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model, Eur. J. Pharm. Biopharm. 72 (2009) 1-8; DOI: 10.1016/j.ejpb.2008.12.013.
- 9. United States Pharmacopoeia 32, National Formulary 29, USP Convention, Rockville 2002.
- 10. J. Varshosaz, J. Emami, N. Tavakoli, A. Fassihi, M. Minaiyan, F. Ahmadi and F. Dorkoosh, Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis, Int. J. Pharm. 365 (2009) 69-76; DOI: 10.1016/j.ijpharm.2008.08.034.
- 11. J. Ding, X. Wang, T. Zhang, Q. Li and M. Luo, Optimization of RP-HPLC analysis of low molecular weight organic acids in soil, J. Liq. Chrom. Rel. Tech. 29 (2006) 99-111; DOI: 10.1080/10826070500363050.
- 12. T. Higuchi, Mechanism of sustained-action medication, J. Pharm. Sci. 52 (1963) 1145-1149; DOI: 10.1002/jps. 2600521210.
- 13. R. W. Korsmeyer, R. Gurny, E. Doelker, P. Buri and N. A. Peppas, Mechanisms of solute release from porous hydrophilic polymers, Int. J. Pharm. 15 (1983) 25-35; DOI: 10.1016/0378-5173(83)90064-9.
- 14. N. A. Peppas, Analysis of Fickian and non-Fickian drug release from polymers, Pharm. Acta Helv. 60 (1985) 110-111.
- 15. P. Costa and J. M. Sonsa Lobo, Modelling and comparison of dissolution profiles, Eur. J. Pharm. Sci. 13 (2001) 123-133; DOI: 10.1016/S0928-0987(01)00095-1.
- 16. G. P. Morris, P. L. Beck, M. S. Herridge, W. T. Depew, M. R. Szewczuk and J. L. Wallace, Hapten-induced model of colonic inflammation and ulceration in the rat colon, Gastroenterology 96 (1989) 795-803.
- 17. S. Choudhary, A. Keshavarzian, S. Yong, M. Wade, S. Bocckino, B. J. Day and A. Banan, Novel antioxidants zolimid and AEOL11201 ameliorate colitis in rats, Dig. Dis. Sci. 46 (2001) 2222-2230; DOI: 10.1023/A: 1011975218006.
- 18. S. Y. Zhou, Q. B. Mei, L. Liu, X. Guo, B. S. Qiu, D. H. Zhao and C. H. Cho, Delivery of glucocorticoid conjugates in rat gastrointestinal tract and its treatment for ulcerative colitis, Acta Pharmacol. Sin. 22 (2001) 761-764.
- 19. J. L. Wallace and C. M. Keenan, An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis, Am. J. Physiol. 258 (1990) 527-534.
- 20. C. B. Appleyard and J. L. Wallace, Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs, Am. J. Physiol. 269 (1995) 119-125.